BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 32895958)

  • 1. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma.
    Nishiwada S; Sho M; Cui Y; Yamamura K; Akahori T; Nakagawa K; Nagai M; Nakamura K; Takagi T; Ikeda N; Li W; Baba H; Goel A
    Int J Cancer; 2021 Feb; 148(3):769-779. PubMed ID: 32895958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
    Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
    Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
    J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma].
    Wu L; Guo W; Li Y; Cheng T; Yao Y; Zhang Y; Liu B; Zhong M; Li S; Deng X; Zhu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1171-1178. PubMed ID: 30377133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.
    Kubo H; Murakami T; Matsuyama R; Yabushita Y; Tsuchiya N; Sawada Y; Homma Y; Kumamoto T; Endo I
    World J Surg; 2019 Dec; 43(12):3153-3160. PubMed ID: 31549202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kawasaki Y; Arigami T; Mori S; Kijima Y; Ueno S; Shinchi H; Natsugoe S
    Ann Surg Oncol; 2018 May; 25(5):1432-1439. PubMed ID: 29404819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
    Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunological impact of preoperative chemoradiotherapy on the tumor microenvironment of pancreatic cancer.
    Okubo S; Suzuki T; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Takahashi S; Kojima M
    Cancer Sci; 2021 Jul; 112(7):2895-2904. PubMed ID: 33931909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of endoscopic ultrasound in pancreatic cancer.
    Luz LP; Al-Haddad MA; Sey MS; DeWitt JM
    World J Gastroenterol; 2014 Jun; 20(24):7808-18. PubMed ID: 24976719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
    Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
    Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma.
    Park JK; Lee JH; Noh DH; Park JK; Lee KT; Lee JK; Lee KH; Jang KT; Cho J
    Gut Liver; 2020 May; 14(3):387-394. PubMed ID: 31581388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change Impact of Body Composition During Neoadjuvant Chemoradiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Pancreatectomy.
    Takaichi S; Tomimaru Y; Kobayashi S; Toya K; Sasaki K; Iwagami Y; Yamada D; Noda T; Takahashi H; Asaoka T; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2023 Apr; 30(4):2458-2468. PubMed ID: 36575288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
    Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
    Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic influence of endoscopic ultrasound-guided fine needle aspiration in IPMN-derived invasive adenocarcinoma.
    Suzuki R; Irie H; Takagi T; Sugimoto M; Konno N; Sato Y; Watanabe K; Nakamura J; Marubashi S; Hikichi T; Ohira H
    BMC Cancer; 2018 Oct; 18(1):974. PubMed ID: 30314433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens.
    Rasmussen LG; Verbeke CS; Sørensen MD; Pfeiffer P; Tan Q; Mortensen MB; Fristrup C; Detlefsen S
    Pancreatology; 2021 Apr; 21(3):530-543. PubMed ID: 33637450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
    Preis M; Gardner TB; Gordon SR; Pipas JM; Mackenzie TA; Klein EE; Longnecker DS; Gutmann EJ; Sempere LF; Korc M
    Clin Cancer Res; 2011 Sep; 17(17):5812-21. PubMed ID: 21652542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal Adenocarcinoma.
    Kandimalla R; Tomihara H; Banwait JK; Yamamura K; Singh G; Baba H; Goel A
    Clin Cancer Res; 2020 Jul; 26(14):3641-3648. PubMed ID: 32234757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
    Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
    Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing neoadjuvant chemotherapy with or without radiation therapy for pancreatic ductal adenocarcinoma: National Cancer Database cohort analysis.
    Oba A; Wu YHA; Colborn KL; Karam SD; Meguid C; Al-Musawi MH; Bao QR; Gleisner AL; Ahrendt S; Schulick RD; Del Chiaro M
    Br J Surg; 2022 Apr; 109(5):450-454. PubMed ID: 35136963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.